CA-AMAZON-PRIME-VIDEO
Regular Heroes is an eight-episode docuseries highlighting the contributions and personal sacrifices of just some of today’s most generous individuals who are going above and beyond to support their communities during the COVID-19 crisis. The series premieres on Amazon Prime Video in the U.S., U.K., Canada and Australia on Friday, May 8. In addition to shining the spotlight on the heroes’ tireless work and amplifying their efforts in cities including New York City, Los Angeles, New Orleans, Chicago, and Seattle among others, the series will offer support and assistance with donations of goods, services and more so that they can continue to pay it forward and help their communities. New episodes of Regular Heroes will be available every Friday. The series will premiere in all other Amazon Prime Video territories May 12, 2020.
In the premiere episode of Regular Heroes, Native New Yorker and 15-time Grammy Award-winning singer, producer and author Alicia Keys will help shine a light on Trevor Henry, Burnell Cotlon and Athena Hayley as they each make personal sacrifices for their families and communities. Additionally, Keys’ moving new song, “Good Job,” will be featured in the series. Subsequent episodes with additional talent and heroes will be announced at a later date.
“This show is Amazzziinngg!!! So pure and genuine! I’m happy to know this series will not only give support to but also put a face on the incredible people like Trevor, Burnell and Hayley. They are the ones we clap for each night at 7pm in New York. These are the Heroes. And I’m so honored to celebrate them!!” said Keys.
“We are so proud to celebrate people who are doing so much to transform the lives of people in their communities. This show is inspired by the individuals who give so much to others every day of the year but even more so during this challenging time. They are true role models and we can’t wait to share their stories with Prime Video customers everywhere,” said Jennifer Salke, Head of Amazon Studios.
Episode One (May 8, 2020): “A New Type Of Hero” with a special appearance by Alicia Keys. Featuring:
TREVOR HENRY (NEW YORK CITY)
Trevor Henry, born and raised in the Bronx, is a husband and father of four who works as a Senior Inventory Specialist at HSS (Hospital for Special Surgery).
He spends his 10-hour days supporting doctors and nurses as they tend to the sickest COVID-19 patients in the unit. When Trevor isn’t at the hospital, he’s helping his children with their schoolwork as he swaps shifts with his wife who also is an essential worker at a different hospital in New York.
BURNELL COTLON (NEW ORLEANS)
For the last 10 years, Burnell Cotlon has been a staple in New Orleans’ Lower 9th
Ward. After Hurricane Katrina wiped out all viable businesses in the town, Burnell invested his life savings into building a grocery store – “Burnell’s 9th
Ward Grocery.” As the only grocery store within a 5-mile radius, Burnell continues to service his customers who have been struck with massive layoffs, including donating food to those in need. His life mission is to get the Lower 9th
Ward back on par with the rest of New Orleans.
ATHENA HAYLEY (LOS ANGELES)
After overcoming homelessness, Athena Hayley, who goes by her last name, set out on a mission to help others who found themselves in a similar situation. Never one to give up, once she was off the streets, Hayley rented out the living room of her apartment, just so she could make ends meet and put aside some money to start the “Love My Neighbor Foundation.” For the last five years, Hayley has served as a family figure to the residents at the infamous Skid Row, and through her organization, she helps feed and clothe those in need.
Regular Heroes will feature people making a difference in their cities and communities from all walks of life: Health care and emergency workers, grocery store employees, farmers, bus drivers, delivery personnel, sanitation workers, police officers, and others. If you or someone you know is making an extraordinary difference in their community please visit Regular-Heroes.com to apply.
Regular Heroes is produced by Amazon Studios in association with Philymack, TyTy & Jay Brown Productions and MGM’s Big Fish Entertainment. Philip McIntyre, John Lloyd Taylor, Laurence “Jay” Brown, Tyran “Ty Ty” Smith, Dan Cesareo, Lucilla D’Agostino and Jordana Starr serve as Executive Producers.
About Prime Video
Prime Video offers customers a vast collection of digital videos—all available to watch on practically any device.
- Included with Prime Video: Watch tons of popular movies and TV shows, award-winning Amazon Originals and other exclusives, sports, and more. Think Emmy Award winners Fleabag and The Marvelous Mrs. Maisel, Tom Clancy’s Jack Ryan, Mindy Kaling’s Late Night , Donald Glover’s Guava Island , Academy Award-nominated The Big Sick, Troop Zero, The Boys, Homecoming , Thursday Night Football and licensed and self-published content. Prime Video is available in more than 240 countries and territories worldwide (offers and titles vary based on location).
- Prime Video Channels : Prime members can add channels like HBO, Cinemax, STARZ, SHOWTIME, CBS All Access, NBA League Pass and MLB.tv —no extra apps to download, and no cable required. Only pay for the ones you want, and cancel anytime. View the full list of channels available at amazon.com/channels .
- Rent or Buy : Enjoy new-release movies to rent or buy, entire seasons of current TV shows available to buy, with special deals just for Prime members.
- Instant access : Watch at home or on the go with your choice of hundreds of compatible devices. Stream from the web or using the Prime Video app on your smartphone, tablet, set-top box, game console, or select smart tv. For a complete list of compatible devices, visit amazon.com/howtostream .
- Enhanced experiences : Make the most of every viewing with 4K Ultra HD- and High Dynamic Range (HDR)-compatible content. Go behind the scenes of your favorite movies and TV shows with exclusive X-Ray access, powered by IMDb. Save it for later with select mobile downloads for offline viewing.
Prime Video is just one of many benefits included with a Prime membership, along with fast free shipping on millions of items at Amazon.com, unlimited photo storage, exclusive deals and discounts, and access to ad-free music and Kindle ebooks. To sign-up or start a free trial of Amazon Prime visit: amazon.com/prime .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200507005887/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom